The Risk of Developing Long COVID in Patients with Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?

Arno R. Bourgonje*, Antonius T. Otten

*Corresponding author for this work

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

    3 Downloads (Pure)
    Original languageEnglish
    Pages (from-to)1971-1972
    Number of pages4
    JournalClinical Gastroenterology and Hepatology
    Issue number7
    Publication statusPublished - Jul-2023

    Cite this